Coexistence of Restrictive Lung Disease and Hyperinflation – Evidence‑Based Summary

Definitions and Diagnostic Criteria

Pulmonary Function Testing

Imaging

Clinical Significance and Prognosis

All statements are derived from peer‑reviewed evidence published in the European Respiratory Journal.

Diagnostic Approach to Mild Mixed Airflow Limitation with Volume Loss

Understanding the Spirometric Pattern

• The European Respiratory Society suggests that a spirometric pattern of reduced FEV1, reduced FVC, with a low FEV1/FVC ratio most likely represents obstructive lung disease with gas trapping rather than true mixed restriction-obstruction, and requires measurement of total lung capacity (TLC) to confirm the actual pathophysiology before initiating treatment 5, 6
• Small airway collapse and gas trapping can prevent complete exhalation, artificially lowering FVC, as noted by the European Respiratory Journal 7

Essential Diagnostic Steps

• The European Respiratory Society recommends measuring TLC immediately to differentiate true mixed disease from obstruction with hyperinflation, as TLC below 5th percentile indicates a true restrictive component present 5, 6
• The American Thoracic Society suggests that measuring DLCO can help differentiate parenchymal from extrapulmonary causes and predict mortality, with reduced DLCO suggesting parenchymal disease 6

Differential Diagnosis Based on TLC Results

• If TLC is normal or elevated, the primary diagnosis is likely COPD with gas trapping, characterized by smoking history, symptoms of chronic cough and dyspnea, and dynamic hyperinflation, as noted by the European Respiratory Journal 5, 7
• If TLC is below 5th percentile, true mixed obstruction-restriction should be considered, with potential causes including combined emphysema and pulmonary fibrosis, interstitial lung disease, and sarcoidosis, as suggested by the European Respiratory Journal and Praxis Medical Insights 5, 6, 8

Treatment Approach

• For obstruction with gas trapping, the European Respiratory Society recommends bronchodilator therapy as the cornerstone, even with mild obstruction, with long-acting bronchodilators preferred for symptomatic patients 7
• For true mixed disease, treatment targets both components, with bronchodilators for the obstructive component and disease-specific therapy for the restrictive component, as noted by the European Respiratory Journal and Praxis Medical Insights 7, 8

Severity Classification

• The American Thoracic Society suggests classifying severity by FEV1% predicted only, with mild severity defined as FEV1 ≥80% predicted, moderate as FEV1 60-69% predicted, and so on, as outlined by Praxis Medical Insights 6, 8